[HTML][HTML] Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
DP Silver, AL Richardson, AC Eklund… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2010•ncbi.nlm.nih.gov
Purpose Cisplatin is a chemotherapeutic agent not used routinely for breast cancer
treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary
BRCA1-mutated breast cancers. Because sporadic triple-negative breast cancer (TNBC)
and BRCA1-associated breast cancer share features suggesting common pathogenesis, we
conducted a neoadjuvant trial of cisplatin in TNBC and explored specific biomarkers to
identify predictors of response.
treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary
BRCA1-mutated breast cancers. Because sporadic triple-negative breast cancer (TNBC)
and BRCA1-associated breast cancer share features suggesting common pathogenesis, we
conducted a neoadjuvant trial of cisplatin in TNBC and explored specific biomarkers to
identify predictors of response.
Abstract
Purpose
Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1-mutated breast cancers. Because sporadic triple-negative breast cancer (TNBC) and BRCA1-associated breast cancer share features suggesting common pathogenesis, we conducted a neoadjuvant trial of cisplatin in TNBC and explored specific biomarkers to identify predictors of response.
ncbi.nlm.nih.gov